↓ Skip to main content

Bone metastasis-related signaling pathways in breast cancers stratified by estrogen receptor status

Overview of attention for article published in Journal of Cancer, April 2017
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
2 X users

Citations

dimensions_citation
9 Dimensions

Readers on

mendeley
19 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Bone metastasis-related signaling pathways in breast cancers stratified by estrogen receptor status
Published in
Journal of Cancer, April 2017
DOI 10.7150/jca.13690
Pubmed ID
Authors

Naoki Hayashi, Takayuki Iwamoto, Yuan Qi, Naoki Niikura, Libero Santarpia, Hideko Yamauchi, Seigo Nakamura, Gabriel N. Hortobagyi, Lajos Pusztai, W. Fraser Symmans, Naoto T. Ueno

Abstract

Background: Breast cancer bone metastasis (BCBM)-specific genes have been reported without considering biological differences based on estrogen receptor (ER) status. The aims of this study were to identify BCBM-specific genes using our patient dataset and validate previously reported BCBM-specific genes, and to determine whether ER-status-related biological differences matter in identification of BCBM-specific genes. Methods: We used Affymetrix GeneChips to analyze 365 primary human epidermal growth factor receptor 2 (HER2)-negative invasive breast cancer specimens. Genes that were differentially expressed between patients who developed bone metastasis and those who developed non-bone metastasis were identified using Cox proportional hazards model, and differential expression of gene sets was assessed using gene set analysis. We performed gene set analysis to determine whether biological function associated with bone metastasis were different by ER status using 2,246 functionally annotated gene sets assembled from Gene Ontology data base. Results: Among 16,712 probe sets, 592 were overexpressed in the bone metastasis cohort compared to the non-bone-metastasis cohort (false discovery rate ≤ 0.05). However, no BCBM-specific genes met our significance tests when the cancers were stratified by ER status. In ER-positive and ER-negative breast cancers, 151 and 125 gene sets, respectively, were overexpressed for BCBM and the majority of BCBM-related pathways were different. Of significant gene sets, only 13 gene sets were overlapped between ER-positive and -negative cohorts. Conclusion: ER-positive and ER-negative breast cancers have different biological pathways in BCBM development. We have yet to explore BCBM-related biomarkers and targets considering the biological features associated with BCBM depending on the ER status.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 19 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Sweden 1 5%
Unknown 18 95%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 5 26%
Other 2 11%
Student > Doctoral Student 2 11%
Student > Bachelor 2 11%
Student > Master 2 11%
Other 2 11%
Unknown 4 21%
Readers by discipline Count As %
Medicine and Dentistry 7 37%
Biochemistry, Genetics and Molecular Biology 4 21%
Agricultural and Biological Sciences 2 11%
Nursing and Health Professions 1 5%
Unknown 5 26%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 May 2017.
All research outputs
#20,660,571
of 25,382,440 outputs
Outputs from Journal of Cancer
#803
of 1,611 outputs
Outputs of similar age
#249,837
of 324,806 outputs
Outputs of similar age from Journal of Cancer
#16
of 34 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,611 research outputs from this source. They receive a mean Attention Score of 3.2. This one is in the 38th percentile – i.e., 38% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 324,806 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 34 others from the same source and published within six weeks on either side of this one. This one is in the 44th percentile – i.e., 44% of its contemporaries scored the same or lower than it.